U.K. cost gatekeepers OK Daiichi's Lixiana; J&J Vision Care targets young females with E! partnership;

> The U.K.'s cost watchdog has recommended Daiichi Sankyo's Lixiana for treating and preventing potentially fatal blood clots. Release

> In a Phase II study, Sanofi ($SNY) and Regeneron's ($REGN) PCSK9 prospect, Praluent, produced LDL cholesterol reductions of more than 60% in Japanese patients. Release

> Johnson & Johnson ($JNJ) Vision Care has partnered up with fashion and entertainment broadcaster E! Entertainment Television to reach a young, fashion-forward, female audience with its 1-Day Acuvue Define range of products. More

> In a Phase II study, Roche's ($RHHBY) investigational immunotherapy atezolizumab shrank tumors in people with a specific type of bladder cancer. Release

> Roche ($RHHBY) has launched its FDA-cleared diabetes app with an insulin calculator in the U.S. More

And Finally... The Obama administration has issued new rules that allow closely held for-profit corporations with religious objections to opt out of providing women with insurance coverage for contraceptives. More (sub. req.)

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.